Novartis, on 18th of September, announced the results of a much-awaited five-year-old, VERIFY clinical study at the European Association for the Study of Diabetes (EASD) Annual Meeting. The study was initiated by the pharmaceutical giant to evaluate the long-term benefits of the early intervention combination treatment of metformin plus vildagliptin (Galvus, Novartis) in patients with type 2 diabetes miletus (T2DM).
According to the results, Galvus was observed to be superior to standard of care in newly diagnosed T2DM patients. These results have been simultaneously published in the latest version of ‘‘The Lancet.’’ Novartis, in the year 2012, had started a five-year, multi-center, randomized, double-blind Phase IV VERIFY study (ClinicalTrials.gov Identifier: NCT01528254) to assess the durability of glycemic control of a combination regimen strategy with Galvus in comparison with the…
